| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $277.0M+54.8% | $179.0M+5.1% | $170.3M-8.1% | $185.3M+20.1% | $154.3M+56.9% | $98.4M+15.6% | $85.1M+52.8% | $55.7M+44.8% | $38.4M |
| Cost of revenue | $71.4M-1.0% | $72.1M-4.6% | $75.6M+30.5% | $57.9M+17.5% | $49.3M+118.8% | $22.5M+1.1% | $22.3M+13.2% | $19.7M+25.4% | $15.7M |
| Research and development | $93.8M-8.9% | $103.0M-15.7% | $122.1M-13.9% | $141.8M-0.4% | $142.3M+22.6% | $116.1M+64.2% | $70.7M+80.6% | $39.2M+22.4% | $32.0M |
| Sales and marketing | $94.6M+11.6% | $84.8M-4.3% | $88.6M-7.3% | $95.6M+0.1% | $95.5M+55.6% | $61.4M+59.6% | $38.5M+57.0% | $24.5M+46.1% | $16.8M |
| General and administrative | $72.7M-0.1% | $72.8M-13.3% | $83.9M-5.2% | $88.5M+18.8% | $74.5M+50.4% | $49.5M+63.3% | $30.3M+48.6% | $20.4M+28.0% | $15.9M |
| Amortization of intangible assets | $1.7M-0.2% | $1.7M+0.2% | $1.7M+0.0% | $1.7M+0.0% | $1.7M-0.2% | $1.7M+0.3% | $1.7M-0.1% | $1.7M+0.3% | $1.7M |
| Impairment of long-lived assets | $0-100.0% | $7.2M-71.7% | $25.4M | — | — | — | — | — | — |
| Total operating expenses | $334.1M-2.2% | $341.5M-14.0% | $397.3M+3.1% | $385.5M+6.1% | $363.3M+44.6% | $251.2M+53.7% | $163.5M+55.1% | $105.4M+27.1% | $82.9M |
| Loss from operations | -$57.1M+64.9% | -$162.5M+28.4% | -$227.0M-13.4% | -$200.2M+4.2% | -$209.0M-36.7% | -$152.8M-94.9% | -$78.4M-57.6% | -$49.8M-11.9% | -$44.5M |
| Interest and other income, net | $9.4M-35.0% | $14.5M-6.4% | $15.5M+282.9% | $4.1M+143.2% | $1.7M-74.7% | $6.6M-32.7% | $9.8M+195.7% | $3.3M+101.3% | $1.6M |
| Interest expense | -$11.8M-1.7% | -$11.6M+16.1% | -$13.8M-225.6% | -$4.2M | — | — | — | — | — |
| Net loss | -$59.5M+62.7% | -$159.6M+29.2% | -$225.3M-12.4% | -$200.4M+3.3% | -$207.3M-41.8% | -$146.2M-113.1% | -$68.6M-47.7% | -$46.4M-8.4% | -$42.8M |
| Add: Net (income) loss attributable to noncontrolling interest | -$42K-140.8% | $103K+90.7% | $54K-69.5% | $177K+831.6% | $19K | — | — | — | — |
| Net loss attributable to Adaptive Biotechnologies Corporation | -$59.5M+62.7% | -$159.5M+29.2% | -$225.3M-12.5% | -$200.2M+3.4% | -$207.3M-41.8% | -$146.2M-113.1% | -$68.6M-47.7% | -$46.4M-8.4% | -$42.8M |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | -$390.00+63.9% | -$1080.00+30.8% | -$1560.00-11.4% | -$1400.00+5.4% | -$1480.00-33.3% | -$1110.00 | — | — | — |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | -$390.00+63.9% | -$1080.00+30.8% | -$1560.00-11.4% | -$1400.00+5.4% | -$1480.00-33.3% | -$1110.00 | — | — | — |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | $151721939000.00+3.1% | $147101648000.00+1.9% | $144383294000.00+1.3% | $142515917000.00+1.5% | $140354915000.00+7.0% | $131216468000.00 | — | — | — |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | $151721939000.00+3.1% | $147101648000.00+1.9% | $144383294000.00+1.3% | $142515917000.00+1.5% | $140354915000.00+7.0% | $131216468000.00 | — | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.